Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 56

1.

IND.216: a phase II study of buparlisib and associated biomarkers, raptor and p70S6K, in patients with relapsed and refractory chronic lymphocytic leukemia.

Assouline S, Amrein L, Aloyz R, Banerji V, Caplan S, Owen C, Hasegawa W, Robinson S, Shivakumar S, Prica A, Peters A, Hagerman L, Rodriguez L, Skamene T, Panasci L, Chen BE, Hay AE.

Leuk Lymphoma. 2020 Mar 10:1-7. doi: 10.1080/10428194.2020.1734594. [Epub ahead of print]

PMID:
32154751
2.

Who is eating fructose within the Aedes albopictus gut microbiota?

Guégan M, Tran Van V, Martin E, Minard G, Tran FH, Fel B, Hay AE, Simon L, Barakat M, Potier P, Haichar FEZ, Valiente Moro C.

Environ Microbiol. 2020 Jan 13. doi: 10.1111/1462-2920.14915. [Epub ahead of print]

PMID:
31943686
3.

Feedback Regulation of N Fixation in Frankia-Alnus Symbiosis Through Amino Acids Profiling in Field and Greenhouse Nodules.

Hay AE, Herrera-Belaroussi A, Rey M, Fournier P, Normand P, Boubakri H.

Mol Plant Microbe Interact. 2020 Mar;33(3):499-508. doi: 10.1094/MPMI-10-19-0289-R. Epub 2020 Jan 9.

PMID:
31916486
4.

Can Administrative Data Improve the Performance of Cancer Clinical Trial Economic Analyses?

Hanna TP, Nguyen P, Pater J, O'Callaghan CJ, Mittmann N, Earle CC, Tu D, Jonker D, Hay AE.

J Oncol Pract. 2019 Sep;15(9):e807-e824. doi: 10.1200/JOP.18.00691. Epub 2019 Jul 15.

PMID:
31306036
5.

The economic impact of the transition from branded to generic oncology drugs.

Cheung WY, Kornelsen EA, Mittmann N, Leighl NB, Cheung M, Chan KK, Bradbury PA, Ng RCH, Chen BE, Ding K, Pater JL, Tu D, Hay AE.

Curr Oncol. 2019 Apr;26(2):89-93. doi: 10.3747/co.26.4395. Epub 2019 Apr 1.

6.

CAR T-cells: costs, comparisons, and commentary.

Hay AE, Cheung MC.

J Med Econ. 2019 Jul;22(7):613-615. doi: 10.1080/13696998.2019.1582059. Epub 2019 Mar 21. No abstract available.

PMID:
30747012
7.

Pilot study of the ability to probabilistically link clinical trial patients to administrative data and determine long-term outcomes.

Hay AE, Pater JL, Corn E, Han L, Camacho X, O'Callaghan C, Chong N, Bell EN, Tu D, Earle CC.

Clin Trials. 2019 Feb;16(1):14-17. doi: 10.1177/1740774518815653. Epub 2018 Nov 22.

PMID:
30466310
8.

A phase I study of romidepsin, gemcitabine, dexamethasone and cisplatin combination therapy in the treatment of peripheral T-cell and diffuse large B-cell lymphoma; the Canadian cancer trials group LY.15 study†.

Reiman T, Savage KJ, Crump M, Cheung MC, MacDonald D, Buckstein R, Couban S, Piliotis E, Imrie K, Spaner D, Shivakumar S, Kuruvilla J, Villa D, Shepherd LE, Skamene T, Winch C, Chen BE, Hay AE.

Leuk Lymphoma. 2019 Apr;60(4):912-919. doi: 10.1080/10428194.2018.1515937. Epub 2018 Oct 10.

PMID:
30301414
9.

Attenuation and group speed in water-saturated granular materials at MHz frequencies.

Hare J, Hay AE.

J Acoust Soc Am. 2018 May;143(5):2744. doi: 10.1121/1.5033901.

PMID:
29857714
10.

Understanding the patient perspective on research access to national health records databases for conduct of randomized registry trials.

Avram R, Marquis-Gravel G, Simard F, Pacheco C, Couture É, Tremblay-Gravel M, Desplantie O, Malhamé I, Bibas L, Mansour S, Parent MC, Farand P, Harvey L, Lessard MG, Ly H, Liu G, Hay AE, Marc Jolicoeur E.

Int J Cardiol. 2018 Jul 1;262:110-116. doi: 10.1016/j.ijcard.2017.12.074.

PMID:
29706388
11.

Intergroup LEAP trial (S1612): A randomized phase 2/3 platform trial to test novel therapeutics in medically less fit older adults with acute myeloid leukemia.

Walter RB, Michaelis LC, Othus M, Uy GL, Radich JP, Little RF, Hita S, Saini L, Foran JM, Gerds AT, Klepin HD, Hay AE, Assouline S, Lancet JE, Couban S, Litzow MR, Stone RM, Erba HP.

Am J Hematol. 2018 Feb;93(2):E49-E52. doi: 10.1002/ajh.24980. Epub 2017 Dec 4. No abstract available.

12.

Short-pulse method for acoustic backscatter amplitude calibration at MHz frequencies.

Wilson GW, Hay AE.

J Acoust Soc Am. 2017 Sep;142(3):1655. doi: 10.1121/1.5003788.

PMID:
28964085
13.

Linkage of clinical trial and administrative data: a survey of cancer patient preferences.

Hay AE, Leung YW, Pater JL, Brown MC, Bell E, Howell D, Kassam Z, Willing S, Tian C, Liu G.

Curr Oncol. 2017 Jun;24(3):161-167. doi: 10.3747/co.24.3400. Epub 2017 Jun 27.

14.

Salvage chemotherapy and autologous stem cell transplantation for peripheral T-cell lymphoma: a subset analysis of the Canadian Cancer Trials Group LY.12 randomized phase 3 study.

Skamene T, Crump M, Savage KJ, Reiman T, Kuruvilla J, Good D, LeBrun D, Meyer RM, Sehn LH, Soulières D, Stakiw J, Laferriere N, Luminari S, Shepherd LE, Djurfeldt M, Zhu L, Chen BE, Hay AE.

Leuk Lymphoma. 2017 Oct;58(10):2319-2327. doi: 10.1080/10428194.2017.1312379. Epub 2017 May 15.

PMID:
28504033
15.

Treatment outcomes for older patients with relapsed/refractory aggressive lymphoma receiving salvage chemotherapy and autologous stem cell transplantation are similar to younger patients: a subgroup analysis from the phase III CCTG LY.12 trial.

Davison K, Chen BE, Kukreti V, Couban S, Benger A, Berinstein NL, Kaizer L, Desjardins P, Mangel J, Zhu L, Djurfeldt MS, Hay AE, Shepherd LE, Crump M.

Ann Oncol. 2017 Mar 1;28(3):622-627. doi: 10.1093/annonc/mdw653.

16.

The CDK inhibitor AT7519M in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma. A Phase II study of the Canadian Cancer Trials Group.

Seftel MD, Kuruvilla J, Kouroukis T, Banerji V, Fraser G, Crump M, Kumar R, Chalchal HI, Salim M, Laister RC, Crocker S, Gibson SB, Toguchi M, Lyons JF, Xu H, Powers J, Sederias J, Seymour L, Hay AE.

Leuk Lymphoma. 2017 Jun;58(6):1358-1365. doi: 10.1080/10428194.2016.1239259. Epub 2016 Oct 17.

PMID:
27750483
17.

A pharmacogenetic analysis of the Canadian Cancer Trials Group MY.10 clinical trial of maintenance therapy for multiple myeloma.

Han M, Murugesan A, Bahlis NJ, Song K, White D, Chen C, Seftel MD, Howsen-Jan K, Reece D, Stewart K, Xie Y, Hay AE, Shepherd L, Djurfeldt M, Zhu L, Meyer RM, Chen BE, Reiman T.

Blood. 2016 Aug 4;128(5):732-5. doi: 10.1182/blood-2016-06-716902. Epub 2016 Jun 23. No abstract available.

PMID:
27338095
18.

Effect of the addition of rituximab to salvage chemotherapy prior to autologous stem cell transplant in aggressive CD20+ lymphoma: a cohort comparison from the NCIC Clinical Trials Group Study LY.12<sup/>.

Baetz T, Chen BE, Couban S, Tom Kouroukis C, Buckstein R, Kuruvilla J, Howson-Jan K, Szwajcer D, Federico M, Meyer RM, Djurfeldt MS, Hay AE, Shepherd L, Crump M.

Leuk Lymphoma. 2017 Jan;58(1):64-69. Epub 2016 Jun 7.

PMID:
27266754
19.

Accrual of adolescents and young adults with cancer to clinical trials.

Hay AE, Rae C, Fraser GA, Meyer RM, Abbott LS, Bevan S, McBride ML, Cuvelier GD, McKillop S, Barr RD.

Curr Oncol. 2016 Apr;23(2):e81-5. doi: 10.3747/co.23.2925. Epub 2016 Apr 13. No abstract available.

20.

Estimation of drug cost avoidance and pathology cost avoidance through participation in NCIC Clinical Trials Group phase III clinical trials in Canada.

Tang PA, Hay AE, O'Callaghan CJ, Mittmann N, Chambers CR, Pater JL, Leighl NB.

Curr Oncol. 2016 Feb;23(Suppl 1):S7-S13. doi: 10.3747/co.23.2861. Epub 2016 Feb 29.

21.

Measuring two-phase particle flux with a multi-frequency acoustic Doppler profiler.

Wilson GW, Hay AE.

J Acoust Soc Am. 2015 Dec;138(6):3811-9. doi: 10.1121/1.4938219.

PMID:
26723335
22.

A phase II study of AT9283, an aurora kinase inhibitor, in patients with relapsed or refractory multiple myeloma: NCIC clinical trials group IND.191.

Hay AE, Murugesan A, DiPasquale AM, Kouroukis T, Sandhu I, Kukreti V, Bahlis NJ, Lategan J, Reece DE, Lyons JF, Sederias J, Xu H, Powers J, Seymour LK, Reiman T.

Leuk Lymphoma. 2016;57(6):1463-6. doi: 10.3109/10428194.2015.1091927. Epub 2015 Oct 15. No abstract available.

PMID:
26376958
23.

Correlation of single arm versus randomised phase 2 oncology trial characteristics with phase 3 outcome.

Monzon JG, Hay AE, McDonald GT, Pater JL, Meyer RM, Chen E, Chen BE, Dancey JE.

Eur J Cancer. 2015 Nov;51(17):2501-7. doi: 10.1016/j.ejca.2015.08.004. Epub 2015 Aug 31.

PMID:
26338195
24.

Salvage chemotherapy and autologous stem cell transplantation for transformed indolent lymphoma: a subset analysis of NCIC CTG LY12.

Kuruvilla J, MacDonald DA, Kouroukis CT, Cheung M, Olney HJ, Turner AR, Anglin P, Seftel M, Ismail WS, Luminari S, Couban S, Baetz T, Meyer RM, Hay AE, Shepherd L, Djurfeldt MS, Alamoudi S, Chen BE, Crump M.

Blood. 2015 Aug 6;126(6):733-8. doi: 10.1182/blood-2015-01-622084. Epub 2015 Jun 24.

PMID:
26109202
25.

Gemcitabine/dexamethasone/cisplatin vs cytarabine/dexamethasone/cisplatin for relapsed or refractory aggressive-histology lymphoma: cost-utility analysis of NCIC CTG LY.12.

Cheung MC, Hay AE, Crump M, Imrie KR, Song Y, Hassan S, Risebrough N, Sussman J, Couban S, MacDonald D, Kukreti V, Kouroukis CT, Baetz T, Szwajcer D, Desjardins P, Shepherd L, Meyer RM, Le A, Chen BE, Mittmann N; Committee on Economic Analysis and the Hematology Disease Site Committee, NCIC Clinical Trials Group.

J Natl Cancer Inst. 2015 Apr 13;107(7). pii: djv106. doi: 10.1093/jnci/djv106. Print 2015 Jul.

PMID:
25868579
26.

Alnus peptides modify membrane porosity and induce the release of nitrogen-rich metabolites from nitrogen-fixing Frankia.

Carro L, Pujic P, Alloisio N, Fournier P, Boubakri H, Hay AE, Poly F, François P, Hocher V, Mergaert P, Balmand S, Rey M, Heddi A, Normand P.

ISME J. 2015 Aug;9(8):1723-33. doi: 10.1038/ismej.2014.257. Epub 2015 Jan 20.

27.

Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12.

Crump M, Kuruvilla J, Couban S, MacDonald DA, Kukreti V, Kouroukis CT, Rubinger M, Buckstein R, Imrie KR, Federico M, Di Renzo N, Howson-Jan K, Baetz T, Kaizer L, Voralia M, Olney HJ, Turner AR, Sussman J, Hay AE, Djurfeldt MS, Meyer RM, Chen BE, Shepherd LE.

J Clin Oncol. 2014 Nov 1;32(31):3490-6. doi: 10.1200/JCO.2013.53.9593. Epub 2014 Sep 29.

PMID:
25267740
29.

An individual patient-data comparison of combined modality therapy and ABVD alone for patients with limited-stage Hodgkin lymphoma.

Hay AE, Klimm B, Chen BE, Goergen H, Shepherd LE, Fuchs M, Gospodarowicz MK, Borchmann P, Connors JM, Markova J, Crump M, Lohri A, Winter JN, Dörken B, Pearcey RG, Diehl V, Horning SJ, Eich HT, Engert A, Meyer RM; Conducted by the NCIC Clinical Trials Group (Canada) and German Hodgkin Study Group (GHSG).

Ann Oncol. 2013 Dec;24(12):3065-9. doi: 10.1093/annonc/mdt389. Epub 2013 Oct 11.

30.

A retrospective study of autologous stem cell mobilization to guide an immediate salvage protocol using plerixafor for patients who mobilize stem cells poorly.

Hay AE, Lawrie A, Robinson N, Dong B, Culligan DJ.

J Clin Apher. 2013 Oct;28(5):378-80. doi: 10.1002/jca.21274. Epub 2013 Mar 11.

PMID:
23483573
31.

Antioxidant compounds from Algerian Convolvulus tricolor (Convolvulaceae) seed husks.

Kacem N, Hay AE, Marston A, Zellagui A, Rhouati S, Hostettmann K.

Nat Prod Commun. 2012 Jul;7(7):873-4.

PMID:
22908568
32.

Hepatitis B, rituximab, screening, and prophylaxis: effectiveness and cost effectiveness.

Hay AE, Meyer RM.

J Clin Oncol. 2012 Sep 10;30(26):3155-7. doi: 10.1200/JCO.2012.43.7509. Epub 2012 Aug 13. No abstract available.

PMID:
22891267
33.

Paradoxical effects of polyphenolic compounds from Clusiaceae on angiogenesis.

Lavaud A, Soleti R, Hay AE, Richomme P, Guilet D, Andriantsitohaina R.

Biochem Pharmacol. 2012 Feb 15;83(4):514-23. doi: 10.1016/j.bcp.2011.12.002. Epub 2011 Dec 9.

PMID:
22177987
34.

Lectin genes in the Frankia alni genome.

Pujic P, Fournier P, Alloisio N, Hay AE, Maréchal J, Anchisi S, Normand P.

Arch Microbiol. 2012 Jan;194(1):47-56. doi: 10.1007/s00203-011-0770-1. Epub 2011 Dec 8.

PMID:
22159868
35.

Antioxidant and antigenotoxic properties of compounds isolated from Marrubium deserti de Noé.

Zaabat N, Hay AE, Michalet S, Darbour N, Bayet C, Skandrani I, Chekir-Ghedira L, Akkal S, Dijoux-Franca MG.

Food Chem Toxicol. 2011 Dec;49(12):3328-35. doi: 10.1016/j.fct.2011.08.026. Epub 2011 Sep 6.

PMID:
21924316
36.

Screening medicinal plants for the detection of novel antimalarial products applying the inhibition of β-hematin formation.

Vargas S, Ndjoko Ioset K, Hay AE, Ioset JR, Wittlin S, Hostettmann K.

J Pharm Biomed Anal. 2011 Dec 15;56(5):880-6. doi: 10.1016/j.jpba.2011.06.026. Epub 2011 Jul 5.

PMID:
21872416
37.

Structure elucidation and NMR assignments of two new triterpenoids from the stems of Paragonia pyramidata (Bignoniaceae).

Wang XL, Hay AE, Matheeussen A, Gupta MP, Hostettmann K.

Magn Reson Chem. 2011 Apr;49(4):184-9. doi: 10.1002/mrc.2726. Epub 2011 Mar 9.

PMID:
21391240
38.

The determinants of the actinorhizal symbiosis.

Kucho K, Hay AE, Normand P.

Microbes Environ. 2010;25(4):241-52. Review.

39.

Angular scattering of sound from solid particles in turbulent suspension.

Moore SA, Hay AE.

J Acoust Soc Am. 2009 Sep;126(3):1046-56. doi: 10.1121/1.3180696.

PMID:
19739717
40.

Antioxidant and enzyme inhibition activities and chemical profiles of Polygonum sachalinensis F.Schmidt ex Maxim (Polygonaceae).

Fan P, Terrier L, Hay AE, Marston A, Hostettmann K.

Fitoterapia. 2010 Mar;81(2):124-31. doi: 10.1016/j.fitote.2009.08.019. Epub 2009 Aug 19.

PMID:
19698767
41.

Rapid separation of three glucosylated resveratrol analogues from the invasive plant Polygonum cuspidatum by high-speed countercurrent chromatography.

Fan P, Marston A, Hay AE, Hostettmann K.

J Sep Sci. 2009 Sep;32(17):2979-84. doi: 10.1002/jssc.200900057.

PMID:
19639547
42.

Antioxidant phenylethanoid glycosides and a neolignan from Jacaranda caucana.

Martin F, Hay AE, Quinteros Condoretty VR, Cressend D, Reist M, Gupta MP, Carrupt PA, Hostettmann K.

J Nat Prod. 2009 May 22;72(5):852-6. doi: 10.1021/np900038j.

PMID:
19361168
43.

Antioxidant C-glucosylxanthones from the leaves of Arrabidaea patellifera.

Martin F, Hay AE, Cressend D, Reist M, Vivas L, Gupta MP, Carrupt PA, Hostettmann K.

J Nat Prod. 2008 Nov;71(11):1887-90. doi: 10.1021/np800406q. Epub 2008 Oct 25.

PMID:
18950229
44.

Antileishmanial polyphenols from Garcinia vieillardii.

Hay AE, Merza J, Landreau A, Litaudon M, Pagniez F, Le Pape P, Richomme P.

Fitoterapia. 2008 Jan;79(1):42-6. Epub 2007 Aug 9.

PMID:
17826924
45.

Iridoid glycosides from the stems of Pithecoctenium crucigerum (Bignoniaceae).

Martin F, Hay AE, Corno L, Gupta MP, Hostettmann K.

Phytochemistry. 2007 May;68(9):1307-11. Epub 2007 Mar 23.

PMID:
17382978
46.

Limonoid orthoacetates and antiprotozoal compounds from the roots of Pseudocedrela kotschyi.

Hay AE, Ioset JR, Ahua KM, Diallo D, Brun R, Hostettmann K.

J Nat Prod. 2007 Jan;70(1):9-13.

PMID:
17253841
47.

New and bioactive aromatic compounds from Zanthoxylum zanthoxyloides.

Queiroz EF, Hay AE, Chaaib F, van Diemen D, Diallo D, Hostettmann K.

Planta Med. 2006 Jun;72(8):746-50. Epub 2006 Jun 19.

PMID:
16783692
48.

Bioactive diterpenes from the fruits of Detarium microcarpum.

Cavin AL, Hay AE, Marston A, Stoeckli-Evans H, Scopelliti R, Diallo D, Hostettmann K.

J Nat Prod. 2006 May;69(5):768-73.

PMID:
16724838
49.

Latency of onset of de novo myelodysplastic syndromes.

Wu PS, Hay AE, Thomas GE, Bowen DT.

Haematologica. 2004 Nov;89(11):1392-4.

50.

Antimalarial xanthones from Calophyllum caledonicum and Garcinia vieillardii.

Hay AE, Hélesbeux JJ, Duval O, Labaïed M, Grellier P, Richomme P.

Life Sci. 2004 Nov 5;75(25):3077-85.

PMID:
15474559

Supplemental Content

Support Center